Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: An observational database study

Drug Safety

Volumn 31, Issue 3, 2008, Pages 231-240

  Tirkkonen, Tuire ^a,b   Ryynänen, Anna ^a   Vahlberg, Tero ^a   Irjala, Kerttu ^c   Klaukka, Timo ^d   Huupponen, Risto ^a,e   Laine, Kari ^b,e  

^a UNIVERSITY OF TURKU   (Finland)

^b Medbase Ltd   (Finland)

^c Mehiläinen Ltd   (Finland)

^d SOCIAL INSURANCE INSTITUTION   (Finland)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Drug interactions; Lovastatin, drug interactions; Simvastatin, drug interactions

Indexed keywords

ALANINE AMINOTRANSFERASE; BEZAFIBRATE; CARBAMAZEPINE; CLARITHROMYCIN; CLOFIBRATE; CREATINE KINASE; CYCLOSPORIN; CYTOCHROME P450 INHIBITOR; DILTIAZEM; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; GAMMA GLUTAMYLTRANSFERASE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; SIMVASTATIN; STATINE DERIVATIVE; TRIACYLGLYCEROL; VERAPAMIL;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; FINLAND; HOSPITAL PATIENT; HUMAN; INCIDENCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; MYOPATHY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT;

EID: 39749126121     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831030-00004     Document Type: Article

References (44)

1. 1. PR Hebert JM Gaziano KS Chan 1997 Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials JAMA 278 313 21 9228438 10.1001/jama.1997.03550040069040 1:CAS:528:DyaK2sXltlWrurY%3D Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997; 278: 313–21
2. 2. JR Downs M Clearfield S Weis 1998 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1615 22 9613910 10.1001/jama.279.20.1615 1:STN:280:DyaK1c3ntl2qsw%3D%3D Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–22
3. 3. S Bellosta R Paoletti A Corsini 2004 Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 109 III50 7 15198967 10.1161/01.CIR.0000131519.15067.1f Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109: III50–7
4. 4. F Charatan 2001 Bayer decides to withdraw cholesterol lowering drug BMJ 323 359 10.1136/bmj.323.7309.359 Charatan F. Bayer decides to withdraw cholesterol lowering drug. BMJ 2001; 323: 359
5. 5. R SoRelle 2001 Baycol withdrawn from market Circulation 104 E9015 6 10.1161/hc3301.097470 SoRelle R. Baycol withdrawn from market. Circulation 2001; 104: E9015–6
6. 6. JT Backman C Kyrklund M Neuvonen 2002 Gemfibrozil greatly increases plasma concentrations of cerivastatin Clin Pharmacol Ther 72 685 91 12496749 10.1067/mcp.2002.128469 1:CAS:528:DC%2BD3sXlt1SjsQ%3D%3D Backman JT, Kyrklund C, Neuvonen M, et al. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002; 72: 685–91
7. 7. PJ Neuvonen T Kantola KT Kivisto 1998 Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole Clin Pharmacol Ther 63 332 41 9542477 10.1016/S0009-9236(98)90165-5 1:CAS:528:DyaK1cXisVWnu7o%3D Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332–41
8. 8. KT Kivisto T Kantola PJ Neuvonen 1998 Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin Br J Clin Pharmacol 46 49 53 9690949 10.1046/j.1365-2125.1998.00034.x 1:CAS:528:DyaK1cXkslKru70%3D Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 49–53
9. 9. RW Wang PH Kari AY Lu 1991 Biotransformation of lovastatin: IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes Arch Biochem Biophys 290 355 61 1929403 10.1016/0003-9861(91)90551-S 1:CAS:528:DyaK3MXms12rtb8%3D Wang RW, Kari PH, Lu AY, et al. Biotransformation of lovastatin: IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991; 290: 355–61
10. 10. T Prueksaritanont LM Gorham B Ma 1997 In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s Drug Metab Dispos 25 1191 9 9321523 1:CAS:528:DyaK2sXmvVWnsb4%3D Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25: 1191–9
11. 11. C Kyrklund JT Backman KT Kivisto 2000 Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations Clin Pharmacol Ther 68 592 7 11180018 10.1067/mcp.2000.111414 1:CAS:528:DC%2BD3MXht1Sjs7s%3D Kyrklund C, Backman JT, Kivisto KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000; 68: 592–7
12. 12. M Ucar M Neuvonen H Luurila 2004 Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid Eur J Clin Pharmacol 59 879 82 14691614 10.1007/s00228-003-0700-5 1:CAS:528:DC%2BD2cXhsVOgt74%3D Ucar M, Neuvonen M, Luurila H, et al. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 2004; 59: 879–82
13. 13. TA Jacobson 2004 Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadmin-istered with cytochrome P450 inhibitors Am J Cardiol 94 1140 6 15518608 10.1016/j.amjcard.2004.07.080 1:CAS:528:DC%2BD2cXptFOqtb8%3D Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadmin-istered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94: 1140–6
14. 14. JW Grunden KA Fisher 1997 Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin Ann Pharmacother 31 859 63 9220046 1:STN:280:DyaK2szmtlOmtg%3D%3D Grunden JW, Fisher KA. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother 1997; 31: 859–63
15. 15. M Arnadottir LO Eriksson H Thysell 1993 Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin Nephron 65 410 3 8289991 10.1159/000187521 1:STN:280:DyaK2c7hvFaqug%3D%3D Arnadottir M, Eriksson LO, Thysell H, et al. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993; 65: 410–3
16. 16. C Campana I Iacona MB Regazzi 1995 Efficacy and pharmacokinetics of simvastatin in heart transplant recipients Ann Pharmacother 29 235 9 7606066 1:STN:280:DyaK2MzivFyjsg%3D%3D Campana C, Iacona I, Regazzi MB, et al. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients. Ann Pharmacother 1995; 29: 235–9
17. 17. C Olbricht C Wanner T Eisenhauer 1997 Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporinetreated kidney graft patients after multiple doses Clin Pharmacol Ther 62 311 21 9333107 10.1016/S0009-9236(97)90034-5 1:CAS:528:DyaK2sXmslOrtLw%3D Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporinetreated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311–21
18. 18. NE Azie DC Brater PA Becker 1998 The interaction of diltiazem with lovastatin and pravastatin Clin Pharmacol Ther 64 369 77 9797793 10.1016/S0009-9236(98)90067-4 1:STN:280:DyaK1M%2FhsVGhtQ%3D%3D Azie NE, Brater DC, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64: 369–77
19. 19. O Mousa DC Brater KJ Sunblad 2000 The interaction of diltiazem with simvastatin Clin Pharmacol Ther 67 267 74 10741630 10.1067/mcp.2000.104609 1:CAS:528:DC%2BD3cXis1Ghtro%3D Mousa O, Brater DC, Sunblad KJ, et al. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000; 67: 267–74
20. 20. H Watanabe K Kosuge S Nishio 2004 Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension Life Sci 76 281 92 15531380 10.1016/j.lfs.2004.06.022 1:CAS:528:DC%2BD2cXpsFWrtbw%3D Watanabe H, Kosuge K, Nishio S, et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci 2004; 76: 281–92
21. 21. T Kantola KT Kivisto PJ Neuvonen 1998 Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations Clin Pharmacol Ther 64 177 82 9728898 10.1016/S0009-9236(98)90151-5 1:CAS:528:DyaK1cXlvVyksr4%3D Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177–82
22. 22. PW Wong TA Dillard K Kroenke 1998 Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy South Med J 91 202 5 9496876 10.1097/00007611-199802000-00015 1:STN:280:DyaK1c7ls1Gqsg%3D%3D Wong PW, Dillard TA, Kroenke K. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy. South Med J 1998; 91: 202–5
23. 23. PJ Neuvonen KM Jalava 1996 Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid Clin Pharmacol Ther 60 54 61 8689812 10.1016/S0009-9236(96)90167-8 1:CAS:528:DyaK28XltFSqu7o%3D Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 54–61
24. 24. R Gilad Y Lampl 1999 Rhabdomyolysis induced by simvastatin and ketoconazole treatment Clin Neuropharmacol 22 295 7 10516882 1:STN:280:DyaK1Mvks1Skuw%3D%3D Gilad R, Lampl Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol 1999; 22: 295–7
25. 25. MZ Skrabal JA Stading MS Monaghan 2003 Rhabdomyolysis associated with simvastatin-nefazodone therapy South Med J 96 1034 5 14570351 10.1097/01.SMJ.0000078621.31517.30 Skrabal MZ, Stading JA, Monaghan MS. Rhabdomyolysis associated with simvastatin-nefazodone therapy. South Med J 2003; 96: 1034–5
26. 26. M Thompson S Samuels 2002 Rhabdomyolysis with simvastatin and nefazodone Am J Psychiatry 159 1607 12202291 10.1176/appi.ajp.159.9.1607 Thompson M, Samuels S. Rhabdomyolysis with simvastatin and nefazodone. Am J Psychiatry 2002; 159: 1607
27. 27. RH Jacobson P Wang CJ Glueck 1997 Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone JAMA 277 296 7 9002485 10.1001/jama.277.4.296 1:STN:280:DyaK2s7lsF2rsw%3D%3D Jacobson RH, Wang P, Glueck CJ. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. JAMA 1997; 277: 296–7
28. 28. R Paoletti A Corsini S Bellosta 2002 Pharmacological interactions of statins Atheroscler Suppl 3 35 40 12044584 10.1016/S1567-5688(02)00002-8 1:CAS:528:DC%2BD38XktVKltL0%3D Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atheroscler Suppl 2002; 3: 35–40
29. 29. E Spina C Martines A Fazio 1991 Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine Ther Drag Monit 13 109 12 10.1097/00007691-199103000-00004 1:STN:280:DyaK3M3nt1altQ%3D%3D Spina E, Martines C, Fazio A, et al. Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. Ther Drag Monit 1991; 13: 109–12
30. 30. JT Backman KT Olkkola M Ojala 1996 Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin Epilepsia 37 253 7 8598183 10.1111/j.1528-1157.1996.tb00021.x 1:CAS:528:DyaK28XitV2nt78%3D Backman JT, Olkkola KT, Ojala M, et al. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996; 37: 253–7
31. 31. JG Gillum DS Israel RE Polk 1993 Pharmacokinetic drag interactions with antimicrobial agents Clin Pharmacokinet 25 450 82 8119047 10.2165/00003088-199325060-00005 1:CAS:528:DyaK2cXis1Sgtro%3D Gillum JG, Israel DS, Polk RE. Pharmacokinetic drag interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450–82
32. 32. D Williams J Feely 2002 Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors Clin Pharmacokinet 41 343 70 12036392 10.2165/00003088-200241050-00003 1:CAS:528:DC%2BD38Xlt1Gjtbc%3D Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343–70
33. 33. JT Backman C Kyrklund KT Kivisto 2000 Plasma concentrations of active simvastatin acid are increased by gemfibrozil Clin Pharmacol Ther 68 122 9 10976543 10.1067/mcp.2000.108507 1:CAS:528:DC%2BD3cXmsFamu7s%3D Backman JT, Kyrklund C, Kivisto KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122–9
34. 34. LR Pierce DK Wysowski TP Gross 1990 Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy JAMA 264 71 5 2355431 10.1001/jama.1990.03450010075034 1:STN:280:DyaK3c3os1Smsg%3D%3D Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71–5
35. 35. EP Puijenbroek van PW Buf-Vereijken Du PF Spooren 1996 Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil J Intern Med 240 403 4 9010388 10.1046/j.1365-2796.1996.48879000.x van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, et al. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med 1996; 240: 403–4
36. 36. WHO Collaborating Centre for Drag Statistics Methodology [online]. Available from URL: http://www.whocc.no/atcddd/ [Accessed 2007 Nov 16]
37. 37. PJ Graer JM Vega MF Mercuri 1999 Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin Am J Cardiol 84 811 5 10.1016/S0002-9149(99)00442-7 Graer PJ, Vega JM, Mercuri MF, et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999; 84: 811–5
38. 38. M Arnadottir LO Eriksson JI Germershausen 1994 Low-dose simvastatin is a well-tolerated and efficacious cholesterollowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients Nephron 68 57 62 7991041 10.1159/000188088 1:STN:280:DyaK2M%2FotlSgsQ%3D%3D Arnadottir M, Eriksson LO, Germershausen JI, et al. Low-dose simvastatin is a well-tolerated and efficacious cholesterollowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Nephron 1994; 68: 57–62
39. 39. PW Pflugfelder M Huff R Oskalns 1995 Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial J Heart Lung Transplant 14 613 22 7578166 1:STN:280:DyaK28%2FgtVGrtg%3D%3D Pflugfelder PW, Huff M, Oskalns R, et al. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant 1995; 14: 613–22
40. 40. T Nikolaos G Stylianos N Chryssoula 2004 The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy Med Sci Monit 10 MT50 2 15039653 1:CAS:528:DC%2BD2cXjvFykt74%3D Nikolaos T, Stylianos G, Chryssoula N, et al. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit 2004; 10: MT50–2
41. 41. MJ Murphy MH Dominiczak 1999 Efficacy of statin therapy: possible effect of phenytoin Postgrad Med J 75 359 60 10435174 1:STN:280:DyaK1MzmsVSgsA%3D%3D Murphy MJ, Dominiczak MH. Efficacy of statin therapy: possible effect of phenytoin. Postgrad Med J 1999; 75: 359–60
42. 42. C Kyrklund JT Backman KT Kivisto 2001 Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate Clin Pharmacol Ther 69 340 5 11372002 10.1067/mcp.2001.115542 1:CAS:528:DC%2BD3MXktlyhsL8%3D Kyrklund C, Backman JT, Kivisto KT, et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001; 69: 340–5
43. 43. DR Illingworth JP O’Malley 1990 The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia Metabolism 39 403 9 2182974 10.1016/0026-0495(90)90256-C 1:STN:280:DyaK3c3itVegsg%3D%3D Illingworth DR, O’Malley JP. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia. Metabolism 1990; 39: 403–9
44. 44. Tokola R, Palva E, Sommarberg L. Statins and muscular adverse drag reactions [online]. Available from URL: http://www.nam.fi/uploads/english/Publications/Tabu/tabu52002_eng.pdf [Accessed 2007 Dec 6]